Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Berberine mitigates 5-fluorouracil-induced intestinal mucosal damage without impairing anti-tumor effect of 5-Fu by regulating the intestinal flora

ABSTRACT: Berberine mitigates 5-fluorouracil-induced intestinal mucosal damage without impairing anti-tumor effect of 5-Fu by regulating the intestinal flora

PROVIDER: PRJNA889331 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21857743_1.fastq.gz	Fastqsanger.gz
	SRR21857743_2.fastq.gz	Fastqsanger.gz
	SRR21857744_1.fastq.gz	Fastqsanger.gz
	SRR21857744_2.fastq.gz	Fastqsanger.gz
	SRR21857745_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Berberine mitigates 5-fluorouracil-induced intestinal mucosal damage without impairing anti-tumor effect of 5-Fu by regulating the intestinal flora

Project description:To investigate the mechanism of BBR improved intestinal mucosa induced by 5-fluorouracil-induced in mice

2024-08-15 | GSE215201 | GEO

Berberine for the intestinal metaplasia after endoscopic therapy for early-stage gastric cancer

Project description:Interventions: After the study registry, intestinal metaplasia score of gastric corpus upper gastrointestinal endoscopy and gastric biopsy (updated Sydney system) is evaluated, and only cases with 2 or more score continue to the intervention of (1) or (2) by randomized method. The ratio of (1) and (2) is 2:1 with minimization method. In the cases with 1 or less score, the case finish the study. (1) Berberine group patients take berberine 100mg three times a day (300mg per day) for 180 days (2) No medication follow up group patients don’t take berberine for 180 days;D001599;berberine Primary outcome(s): Improvement rate of histological intestinal metaplasia in gastric corpus Definition: In this study, patients with two or more score of intestinal metaplasia score (updated sydney system) in gastric corpus are intervened. After the intervention with berberine group or control group, patients with one or less the score defined as improved. Primary outcome is improvement rate. Study Design: randomized controlled trial, open(masking not used), no treatment control/standard of care control, parallel assignment, treatment purpose

| 2614516 | ecrin-mdr-crc

Analysis of gene expression profile in 5-fluorouracil (5-FU)-resistant human colon cancer cells

Project description:We analyzed the differentially regulated genes in 5-fluorouracil-resnstant human colon cancer cells to discover novel biomarkers involved in 5-FU resistance in colorectal cancer.

2017-03-27 | GSE56322 | GEO

Transcriptional Profile of the Shigella flexneri Response to Berberine

Project description:Berberine is a natural isoquinoline alkaloid found in Chinese medicinal herbs which is active against a variety of microbial infections. To examine the potential effects of berberine on Shigella flexneri, a whole-genome DNA microarray was constructed and transcriptome analysis of the cellular responses of S.flexneri when exposed to Berberine Chloride (BC) was performed.

2012-03-10 | GSE16714 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of normal mice, colitis mice, normal mice receiving berberine and colitis mice receiving berberine colon transcriptomes

Project description:We had three goals to perform this study: compare normal mice and colitis mice，compare berberine effect in normal mice and compare berberine effect in colitis mice

2022-11-26 | GSE197342 | GEO

MicroRNA expression profiling of primary human hepatocytes after berberine chloride treatment

Project description:Berberine, an isoquinoline alkaloid isolated from many medicinal herbs such as Coptis chinensis, has a wide range of pharmacological effects. Since xenobiotic drug-induced micoRNAs have recently emerged as key regulators in guiding their pharmacological effects and toxicity, we were interested in whether or not micoRNA expression was differentially altered by berberine treatment in liver. Here, we used miRNA microarray to analyze microRNA expression profiles of primary human hepatocytes after berberine chloride treatment or 0.08% DMSO as control. Comparing miRNA profiles of 40 ïM berberine-treated primary human hepatocytes to those of control cells sampled after 2 hours treatment. A 50 mM stock solution of Berberine chloride was prepared in DMSO. Cells were treated with 40 ïM berberine chloride or 0.08% DMSO as control.

2015-12-31 | E-GEOD-53413 | biostudies-arrayexpress

Gene expression profiling of primary human hepatocytes after berberine chloride treatment

Project description:Berberine, an isoquinoline alkaloid isolated from many medicinal herbs such as Coptis chinensis, has a wide range of pharmacological effects. Since xenobiotic drug-induced micoRNAs have recently emerged as key regulators in guiding their pharmacological effects and toxicity, we were interested in whether or not micoRNA expression was differentially altered by berberine treatment in liver. Here, we used miRNA microarray to analyze microRNA expression profiles of primary human hepatocytes after berberine chloride treatment or 0.08% DMSO as control. Comparing gene expression profiles of 40 ï?M berberine-treated primary human hepatocytes to those of control cells sampled after 2, 4, or 8 hours treatment. A 50 mM stock solution of Berberine chloride was prepared in DMSO. Cells were treated with 40 ï?M berberine chloride or 0.08% DMSO as control.

2015-12-31 | E-GEOD-53415 | biostudies-arrayexpress

MicroRNA expression profiling of HepG2 liver cells after berberine chloride treatment

Project description:Berberine, an isoquinoline alkaloid isolated from many medicinal herbs such as Coptis chinensis, has a wide range of pharmacological effects including anti-cancer effects. Since xenobiotic drug-induced micoRNAs have recently emerged as key regulators in guiding their pharmacological effects and toxicity, we were interested in whether or not micoRNA expression was differentially altered by berberine treatment in HCC. Here, we used miRNA microarray to analyze microRNA expression profiles of HepG2 human hepatoma cell line after berberine chloride treatment or 0.08% DMSO as control. Comparing miRNA profiles of 40 M-BM-5M-BM--M berberine-treated HepG2 human hepatoma cell line to those of control cells sampled after 2 and 4 hours treatment. A 50 mM stock solution of Berberine chloride was prepared in DMSO. Cells were treated with 40 M-BM-5M-BM--M berberine chloride or 0.08% DMSO as control.

2013-10-17 | E-GEOD-47821 | biostudies-arrayexpress

intestinal flora

Project description:Most of the bacteria in the intestinal flora Genome sequencing

| PRJNA1098963 | ENA

5-Fluorouracil-induced intestinal mucositis via nuclear factor-κB activation

Project description:5-Fluorouracil (5-FU) is a commonly used drug for the treatment of malignant cancers. However, approximately 80% of patients undergoing 5-FU treatment suffer from gastrointestinal mucositis. The aim of this report was to identify the critical molecule involved in 5-FU-induced intestinal mucositis. Our data showed that 5-FU induced inflammation in the small intestine, characterized by the increased intestinal wall thickness and crypt length and the decreased villus height. Network analysis of 5-FU-affected genes by transcriptomic tool showed that the expression of genes was regulated by nuclear factor-κB (NF-κB), and NF-κB was the central molecule in the 5-FU-regulated biological network. NF-κB activity was activated by 5-FU in the intestine, which was judged by bioluminescence imaging and immunohistochemical staining. However, 5-aminosalicylic acid (5-ASA) inhibited 5-FU-induced NF-κB activation and proinflammatory cytokine production. Moreover, 5-FU-induced histological changes were improved by 5-ASA. In conclusion, our findings suggested that NF-κB was the critical molecule associated with the pathogenesis of 5-FU-induced mucositis, and inhibition of NF-κB activity ameliorated the mucosal damage caused by 5-FU.

2017-02-09 | GSE28873 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data